Why it matters
Ibogaine is where psychedelic medicine, addiction care, safety risk, veterans policy, and state-led drug-development ambition collide. Texas’s IMPACT effort is important precisely because the public record separates political authorization and institutional announcement from contract completion and patient enrollment.
Texas IMPACT status ladder
The clean read is a status ladder. Chapter 491 authorizes the framework. Texas HHS says it requested proposals and selected UTHealth Houston as lead institution. The UTMB / UTHealth announcement describes a $50 million HHSC award and a statewide IMPACT partnership.
But HHS also says recent plans did not meet statutory requirements tied to matching state funds and allocation of intellectual-property / revenue rights. So the safest current wording is: authorized, selected, and announced — not yet safely contracted, funded/disbursed, FDA-cleared, enrolling, or running.
IMPACT consortium and targets
The institutional announcement expands IMPACT as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma. It names addiction, traumatic brain injury, and other behavioral-health conditions as targets, and frames the effort as a two-year multicenter research trial effort led by UTHealth Houston and UTMB Health.
The named network includes UTHealth Houston, UTMB Health, Texas Tech University, Texas Tech University Health Sciences Center El Paso, UT Austin, UT Health San Antonio, UT Tyler, UT Rio Grande Valley, Texas A&M University, the University of North Texas Health Science Center, Baylor College of Medicine, and JPS Health Network in Dallas.
Why the caveat matters
Chapter 491 makes the program more than a press-release concept. It asks for a consortium, FDA strategy, participant recruitment, cardiac safety, administration and aftercare plans, data integrity, breakthrough-therapy strategy, intellectual-property and revenue planning, payer/access considerations, provider credentialing, and verified nonstate matching funds.
That is why the HHS caveat controls the live status language. It is possible for Texas to be serious about ibogaine development while the program is still blocked or unfinished at the contract-and-matching-funds layer.
Source trail
Research question: what can SCM safely say about the Texas IMPACT ibogaine effort right now?
Primary source answer: Texas has a statutory framework, HHSC selected UTHealth Houston as lead institution, and UTMB / UTHealth announced the IMPACT consortium and $50 million award framing. The same HHS page also says recent plans did not meet requirements around matching funds and intellectual-property / revenue allocation.
What this proves: authorization, selection, public institutional announcement, named partner network, and an explicit state-level caveat. What it does not prove: contract completion, funds disbursement, FDA clearance, active enrollment, trial launch, or clinical efficacy.
SCM reading rule
For reporting, keep ibogaine claims attached to the source layer: compound background, clinical-use history, safety risk, statutory authorization, state selection, institutional announcement, and actual trial enrollment are different facts. The Texas IMPACT explainer is the live narrative companion to this dossier.
This page is reporting and reference context. It is not medical advice, treatment guidance, dosing guidance, legal advice, or a recommendation to use any substance.